Upload
lionel-john-wilkerson
View
214
Download
1
Tags:
Embed Size (px)
Citation preview
Heart Transplant:Still the Most Cost Effective and Durable Treatment for
Advanced Heart Failure
Arsalan Shirwany, MD
Stern Cardiovascular Foundation
Baptist Transplant & Mechanical Circulatory Support Center
Clinical Assistant Professor of Medicine
University of Tennessee Health Science Center, Memphis
No relevant financial relationships to disclose
Congestive Heart Failure
• CHF Not one disease entity, rather a syndrome
Many disease processes, sometimes present concurrently
• Inability of heart to meet metabolic demands at normal filling pressure
Increasing prevalence High morbidity and mortality High cost Prognosis worse than most malignancies
CHF: Incidence and Prevalence
• NHLBI Study 5.7 million 2012 prevalence
870,000 new cases annually
• Framingham Data 1 in 5 above 40 will develop HF
• NCHS and NHLBI One in 9 deaths has HF listed on death certificate
~285,000 deaths annually from 1995 to 2011
~50% of patients diagnosed with HF will die within 5 years
Projected US prevalence of HF from 2012 to 2030 is shown for different races.
Heidenreich P A et al. Circ Heart Fail. 2013;6:606-619
Copyright © American Heart Association, Inc. All rights reserved.
CHF: Healthcare Use
• 2000 through 2010: ~1,000,000 hospital discharges
• 2010: 1,800,100 physician office visits
• 2010: 676,000 ER visits
• 2012 HF cost: $30.7 billion
• Projected to increase to $69.7 billion by 2030
The projected increase in direct and indirect costs attributable to HF from 2012 to 2030 is displayed.
Heidenreich P A et al. Circ Heart Fail. 2013;6:606-619
Copyright © American Heart Association, Inc. All rights reserved.
CHF: NYHA Classification
Class Functional Capacity: How patients feel during physical activity
IPatients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.
IIPatients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
IIIPatients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain.
IV
Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases.
CHF: ACC/AHA Stages
• Stage A: At high risk for HF but without HF symptoms or structual HD
• Stage B: Structural heart disease but no signs or symptoms of HF
• Stage C: Structural heart disease with prior or current symptoms of HF
• Stage D: Refractory HF requiring specialized intervention
Routine “Annual Heart Failure Review” with a scheduled clinic visitEvent-driven “milestones” that should prompt reassessment Increased symptom burden and/or decreased quality of life Significant decrease in functional capacity Loss of ADLs Falls
Transition in living situation (independent to assisted or LTC)
Worsening HF: hospitalization, particularly if recurrent
Serial increases of maintenance diuretic dose
Symptomatic hypotension, azotemia, or refractory fluid retention
Circulatory-renal limitations to ACEI/ARB
Decrease or discontinuation of β-blockers because of hypotension
First or recurrent ICD shock for VT/VF Initiation of intravenous inotropic support Consideration of renal replacement therapy
Circulation: 2012;1251928-1952
CHF: Shared Decision Making
Circulation: 2012;1251928-1952
Transplantation
• Offers symptom relief and improves survival
• Long term survival Improved with
donor selection harvest techniques Immunosuppression Management of risk factors and comorbidities
Transplant: Centers
JHLT. 2014 Oct; 33(10): 975-984
Transplant: Centers
Adult and Pediatric Heart TransplantsAverage Center Volume (Transplants: January 2006 – June 2013)
JHLT. 2014 Oct; 33(10): 996-1008
Trends in heart transplantations, 1975 to 2013.
Mozaffarian D et al. Circulation. 2015;131:e29-e322
Copyright © American Heart Association, Inc. All rights reserved.
Adult Heart TransplantsDiagnosis
2014 For some retransplants diagnosis other than retransplant was reported, so the total percentage of retransplants may be greater.
JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart Transplants Diagnosis by Location and Era
Europe North America Other2014 For some retransplants diagnosis other than retransplant is
reported, so the total percentage of retransplants may be greater.
JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart Transplants % of Patients Bridged with Mechanical Circulatory Support*
(Transplants: January 2000 – December 2012)
* LVAD, RVAD, TAH, ECMO2014JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart Transplants % of Patients Bridged with Mechanical Circulatory Support* by Year
and Device Type
* LVAD, RVAD, TAH, ECMO2014JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart TransplantsRecipient BMI Distribution by Location
(Transplants: January 2006 – June 2013)
2014JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart TransplantsRecipient Diabetes Mellitus Distribution by Location
(Transplants: January 2006 – June 2013)
2014JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart TransplantsRecipient Cigarette History by Location
(Transplants: January 2006 – June 2013)
2014JHLT. 2014 Oct; 33(10): 996-1008
Transplant: Work-Up
• Cardiac: LV/RV Function
Functional Capacity
Hemodynamics
Transplant Work-Up
• Medical Pulmonary status
Renal function
Hematology
Oncology
Infectious Disease
GI
Hepatology
Endocrine
• Psycho-social
• Physical/Dietary/Pharmacy
UNOS Status Criteria
• Status 1 A PA catheter with High Dose Inotropic support
LVAD 30 days post implant- use at discretion, Device Malfunction
IABP, BiVAD present, ECMO
• Status 1 B Home on inotropic support
LVAD (other than 30 days)
Angina- uncontrolled
• Status 2 – out of hospital
• Status 7 - Inactive
Cardiac Transplantation
• Pre
Standard medical care Repeat RHC Functional assessment
Cardiac Transplantation
• Post- Hospital
Standard ICU post op care Medical therapy
Immunosuppression Comorbid conditions Recovery and Rehab Surveillance biopsy
Cardiac Transplantation
• Long term Immunosuppression
Corticosteroids CNI Anti-Proliferative mTOR inhibitors
Comorbid conditions HTN DM Hyperlipidemia
Infection Prophylaxis
Adult Heart TransplantsCumulative Morbidity Rates in Survivors within 1, 5 and 10 Years Post
Transplant (Follow-ups: January 1995 – June 2013)
OutcomeWithin 1 Year
Total N with known
response
Within 5 Years
Total N with known
response
Within 10 Years
Total N with
known response
Hypertension* 71.8% (N = 28,163) 91.7% (N = 13,023) -
Renal Dysfunction 25.8% (N = 31,118) 51.7% (N = 15,769) 68.1% (N = 5,428)
Abnormal Creatinine ≤ 2.5 mg/dl 17.7% 33.1% 38.5%
Creatinine > 2.5 mg/dl 6.3% 14.6% 20.0%
Chronic Dialysis 1.5% 2.9% 6.0%
Renal Transplant 0.3% 1.1% 3.6%
Hyperlipidemia* 59.8% (N = 29,413) 87.6% (N = 14,372) -
Diabetes* 24.8% (N = 31,120) 37.5% (N = 15,458) -
Cardiac Allograft Vasculopathy 7.8% (N = 28,259) 30.1% (N = 11,511) 49.7% (N = 3,146)
* Data are not available 10 years post transplant
JHLT. 2014 Oct; 33(10): 996-1008
Cardiac Transplantation
• Long term complications Rejection
Cardiac allograft vasculopathy (CAV)
Infections
Chronic Renal insufficiency
Malignancy
Adult Heart Transplants % of Recipients Experiencing Treated Rejection Between
Transplant Discharge and 1-Year Follow-Up by Year
Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.
Adult Heart TransplantsKaplan-Meier Survival by Treatment for Rejection Within 1st Year
(1 Year Follow-ups: January 2005 – June 2011) Conditional on survival to 1 year
All pair-wise comparisons were significant at p < 0.0001 except No rejection vs. Untreated rejection (p = 0.8528)
Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents.
Heart Transplant: Survival(Transplants: January 1982 – June 2012)
All pair-wise comparisons were significant at p < 0.0001 except 2002-2005 vs. 2006-6/2012 (p = 0.9863).
2014JHLT. 2014 Oct; 33(10): 996-1008
All pair-wise comparisons were significant at p < 0.001 except 1992-2001 vs. 2006-6/2012 (p=0.3066) and 2002-2005 vs. 2006-6/2012 (p=0.0804).
JHLT. 2014 Oct; 33(10): 996-1008
Heart Transplant: Survival(Transplants: January 1982 – June 2012)
Adult Heart TransplantsCause of Death (Deaths: January 1994 – June 2013)
CAUSE OF DEATH 0-30 Days (N = 5,609)
31 Days – 1 Year
(N = 4,800)
>1 Year – 3 Years
(N = 3,511)
>3 Years – 5 Years
(N = 3,085)
>5 Years –10 Years
(N = 7,717)
>10 Years – 15 Years (N = 5,186)
>15 Years (N = 2,959)
Cardiac Allograft Vasculopathy 81 (1.4%) 176 (3.7%) 423 (12.0%) 427 (13.8%) 1,055 (13.7%) 706 (13.6%) 345 (11.7%)
Acute Rejection 256 (4.6%) 457 (9.5%) 357 (10.2%) 149 (4.8%) 149 (1.9%) 47 (0.9%) 18 (0.6%)
Lymphoma 3 (0.1%) 57 (1.2%) 84 (2.4%) 104 (3.4%) 286 (3.7%) 154 (3.0%) 75 (2.5%)
Malignancy, Other 2 (0.0%) 117 (2.4%) 424 (12.1%) 592 (19.2%) 1,633 (21.2%) 1,090 (21.0%) 568 (19.2%)
CMV 3 (0.1%) 51 (1.1%) 17 (0.5%) 6 (0.2%) 7 (0.1%) 3 (0.1%) 0
Infection, Non-CMV 713 (12.7%) 1,470 (30.6%) 432 (12.3%) 311 (10.1%) 813 (10.5%) 538 (10.4%) 333 (11.3%)
Graft Failure 2,186 (39.0%) 827 (17.2%) 914 (26.0%) 695 (22.5%) 1,406 (18.2%) 885 (17.1%) 487 (16.5%)
Technical 411 (7.3%) 74 (1.5%) 24 (0.7%) 26 (0.8%) 89 (1.2%) 67 (1.3%) 40 (1.4%)
Other 330 (5.9%) 340 (7.1%) 288 (8.2%) 245 (7.9%) 627 (8.1%) 355 (6.8%) 247 (8.3%)
Multiple Organ Failure 1,010 (18.0%) 746 (15.5%) 213 (6.1%) 191 (6.2%) 531 (6.9%) 429 (8.3%) 272 (9.2%)
Renal Failure 30 (0.5%) 48 (1.0%) 53 (1.5%) 94 (3.0%) 438 (5.7%) 433 (8.3%) 291 (9.8%)
Pulmonary 167 (3.0%) 186 (3.9%) 142 (4.0%) 143 (4.6%) 335 (4.3%) 221 (4.3%) 137 (4.6%)
Cerebrovascular 417 (7.4%) 251 (5.2%) 140 (4.0%) 102 (3.3%) 348 (4.5%) 258 (5.0%) 146 (4.9%)
Total Deaths (N) 6,363 5,481 4,222 3,781 9,534 6,679 3,874
Percentages represent % of deaths in the respective time period. Total number of deaths includes deaths with unknown causes.
JHLT. 2014 Oct; 33(10): 996-1008
Adult Heart Transplants Relative Incidence of Leading Causes of Death
(Deaths: January 1994 – June 2012)
Transplant: Cost-effective?
• Expensive Work-up
Surgery
Follow-up Medications Surveillance testing
Labs Diagnostic imaging Cath, biopsy Complications
• Difficult to estimate
Decision-analytic model diagram for treatment of end-stage heart failure.
Long E F et al. Circ Heart Fail. 2014;7:470-478
Model-projected survival during 5 years.
Long E F et al. Circ Heart Fail. 2014;7:470-478
Copyright © American Heart Association, Inc. All rights reserved.
Cost-effectiveness of end-stage heart failure therapy options.
Long E F et al. Circ Heart Fail. 2014;7:470-478
Copyright © American Heart Association, Inc. All rights reserved.
Transplant: Summary
• Advance Heart Failure Affects ~10% of patients with CHF
Associated with high mortality- more than 50% at one year, close to 80% at two years
• Cardiac Transplant Offers symptom relief
Much longer survival: life expectancy of 8.5 yrs vs 1.1 yr
Average cost ~$97000 per Quality adjusted life year